Aortic thrombosis in young women with Crohn's disease receiving adalimumab: Report of two cases

Inflammatory Bowel Diseases

Volumn 17, Issue 3, 2011, Pages 862-863

  Leblanc, Sarah ^a   Linares, Celia Lloret ^a   Cacheux, Wulfran ^a   Mouthon, Luc ^a   Chaussade, Stanislas ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTICOAGULANT AGENT; HEPARIN; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ABDOMINAL AORTA; ADULT; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; AORTA THROMBOSIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; LEG PAIN; LETTER; PRIORITY JOURNAL; REVASCULARIZATION; SURGICAL THROMBECTOMY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AORTIC DISEASES; CROHN DISEASE; FEMALE; HUMANS; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951595531     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21397     Document Type: Letter

References (8)

1. Carter MJ, Lobo AJ, Travis SP,. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 (suppl 5): V1-16. (Pubitemid 39120096)
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed.). Chest. 2008; 133: 381S-453S. (Pubitemid 351894916)
3. Bernstein CN, Wajda A, Blanchard JF,. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol. 2008; 6: 41-45. (Pubitemid 50008413)
4. Ha C, Magowan S, Accortt NA, et al. Risk of arterial thrombotic events in inflammatory bowel disease. Am J Gastroenterol. 2009; 104: 1445-1451.
5. Novacek G, Haumer M, Schima W, et al. Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis. 2004; 10: 430-435. (Pubitemid 39029187)
6. Atzeni F, Sarzi-Puttini P, Dell'Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther. 2006; 8: R3.
7. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-alpha agents. Ann N Y Acad Sci. 2005; 1051: 559-569.
8. Grainge MJ, West J, Card TR,. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010: 375: 657-663.